Abstracts tagged "Polyarteritis nodosa"

Abstract Number: 096 • 2023 Pediatric Rheumatology Symposium
DADA2 – a Case Series from North India
Manjari Agarwal, Jyotsna verma, ratna puri and Sujata Sawhney, Sir Ganga Ram Hospital, New Delhi, India
Background/Purpose: We present a series of children previously diagnosed and managed as Polyarteritis nodosa at our unit. Due to ease of availability of mutation analysis…
Abstract Number: 2232 • ACR Convergence 2022
Clinical Features and Long-term Outcomes of Patients with Systemic Polyarteritis Nodosa Diagnosed Since 2005: Data from 196 Patients
Julien ROHMER¹, ludovic trefond², Yann Nguyen³, Christian Agard⁴, Jean Sebastien ALLAIN⁵, Alice Berezne⁶, Pierre Charles⁷, Pascal Cohen⁸, guillaume gondran⁹, Matthieu GROH¹⁰, Tessa HUSCENOT¹¹, carole lacout¹², Estibaliz Lazaro¹³, Jonathan London¹⁴, Francois Maurier¹⁵, Arsene Mekinian¹⁶, Isabelle Nubourgh¹⁷, Rafik MESBAH¹⁸, Xavier Puéchal⁸, Laurent Perard¹⁹, Mathieu Puyade²⁰, Gregory Pugnet²¹, Viviane Queyrel²², Diane Rouzaud²³, Arthur Roux²⁴, Cecile-Audrey DUREL¹⁹, Loïc Guillevin⁸ and Benjamin Terrier⁸, ¹APHP, Suresnes, France, ²Chu clermont ferrand, Clermont-Ferrand, France, ³AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵CHU rennes, Rennes, ⁶CH Annecy, Annecy, France, ⁷Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁹CHU limoges, Limoges, France, ¹⁰Foch Hospital, Suresnes, France, ¹¹APHP, Boulogne, France, ¹²CHU Angers, Angers, France, ¹³Bordeaux Hospital University, Bordeaux, France, ¹⁴Hôpital Croix-Saint-Simon, Paris, France, ¹⁵Hôpitaux privés de Metz, Metz, France, ¹⁶AP-HP, Hopital Saint Antoine, Paris, France, ¹⁷Ch St Pierre, Brussels, Belgium, ¹⁸Boulogne Ch, Boulogne, France, ¹⁹CHU Lyon, Lyon, France, ²⁰Centre Hospitalier Universitaire de Poitiers, Poitiers, France, ²¹CHU Toulouse Purpan Service de Medecine Interne, Toulouse, France, ²²CHU NIce, Nice, France, ²³Bichat, Paris, France, ²⁴MGEN, Paris, France
Background/Purpose: The etiological landscape of systemic polyarteritis nodosa (PAN) has substantially changed since the onset of hepatitis B virus (HBV) vaccination and the discovery of…
Abstract Number: 1880 • ACR Convergence 2021
Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa
Jason Springer¹, Tanaz Kermani², Dianne Shaw³, Kalen Young³, Cristina Burroughs⁴ and Peter Merkel⁵, ¹Vanderbilt University Medical Center, Franklin, TN, ²University of California Los Angeles, West Hills, CA, ³Vasculitis Foundation, Kansas City, MO, ⁴Health Informatics Institute, Tampa, FL, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Polyarteritis nodosa (PAN) is form of medium-vessel vasculitis with an estimated annual incidence of 1 per million. The rarity of the disease makes traditional…
Abstract Number: 1884 • ACR Convergence 2021
Real-life Data for the Use of Anti-TNF Treatment in DADA2
Omer Karadag¹, Gizem Ayan², Ozge Basaran³, Ertugrul Cagri bolek⁴, Levent Kilic², Yelda Bilginer⁵, Mehmet Alikasifoglu⁶ and Seza Ozen⁷, ¹Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Hacettepe University Pediatric Rheumatology, Ankara, Turkey, ⁴Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁵Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ⁶Hacettepe University, Department of Medical Genetics, Ankara, Turkey, ⁷Hacettepe University Faculty of Medicine, Pediatric Romatology, Ankara, Turkey
Background/Purpose: Deficiency of adenosine deaminase 2 enzyme (DADA2) is an autosomal recessive autoinflammatory disorder associated with ADA2 mutations. ADA2 works as a growth factor and…
Abstract Number: 0418 • ACR Convergence 2020
Prevalence of Thyroid Disease Among Patients with Vasculitis
Tanaz Kermani¹, David Cuthbertson², Simon Carette³, Nader Khalidi⁴, Curry L. Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih¹³, Kenneth Warrington¹² and Peter Merkel¹³, ¹David Geffen School of Medicine / University of California, Los Angeles, CA, ²University of South Florida, Tampa, ³Division of Rheumatology, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah, Salt Lake City, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, ⁸Brigham and Women's, Boston, ⁹University of Pittsburgh, Denver, CO, ¹⁰Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Previous studies have reported higher risk of thyroid disease in patients with giant cell arteritis (GCA) and ANCA-associated vasculitis (AAV) compared to age- and…
Abstract Number: 1429 • ACR Convergence 2020
An Evaluation of Real World Use of Biologics in Rare Systemic Vasculitides During Routine Clinical Care in the US
Kathryn Starzyk¹, Kimberly Milberg¹, Ashish Deshpande¹ and Gary Curhan¹, ¹OM1, Inc, Boston, MA
Background/Purpose: The mainstay of treatment for vasculitis has been corticosteroids and other cytotoxic and immunosuppressive medications (e.g., cyclophosphamide, methotrexate) to promptly achieve and maintain remission.…
Abstract Number: 1685 • 2019 ACR/ARP Annual Meeting
Inpatient Burden, Expenditures and Comorbidities of Polyarteritis Nodosa: National Inpatient Sample 2014
Patompong Ungprasert¹, Matthew Koster ², Wisit Cheungpasitporn ³, Karn Wijarnpreecha ⁴, Charat Thongprayoon ² and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mayo Clinic Rochester, Rochester, MN, ³University of Mississippi Medical Center, Jackson, MS, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Due to the rarity of polyarteritis nodosa (PAN), no study has ever investigated inpatient characteristics, healthcare utilization and frequency of comorbidities of patients with…
Abstract Number: 1689 • 2019 ACR/ARP Annual Meeting
Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Polyarteritis Nodosa
Alice Canzian ¹, Omer Karadag ², Anne Contis ³, François Maurier ⁴, Silvia Sartorelli ⁵, Laure Denis ⁶, Sébastien Sanges ⁷, Claire de Moreuil ⁸, Cécile-Audrey Durel ⁹, Stéphane Durupt ¹⁰, Marie Jachiet ¹¹, Diane Rouzaud ¹², Carlo Salvarani ¹³, Franco Schiavon ¹⁴, Lorenzo Dagna ¹⁵, Fabrice Bonnet ¹⁶, David Jayne ¹⁷, Loic Guillevin ¹⁸ and Benjamin Terrier¹, ¹Cochin Hospital, Paris, France, ²Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey, ³Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France, Bordeaux, France, ⁴Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ⁵Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, ⁶Clermont-Ferrand Hospital, Clermont-Ferrand, France, ⁷CHRU Lille, Lille, France, ⁸CHU Brest, Brest, France, ⁹Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹⁰Lyon Hospital, Lyon, France, ¹¹Saint Louis Hospital, Paris, France, ¹²Bichat Hospital, Paris, France, ¹³Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁴Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, Padova, Italy, ¹⁵Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ¹⁶CHU Bordeaux, Bordeaux, France, ¹⁷Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ¹⁸National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis of medium- and small-sized arteries, not associated with antineutrophil cytoplasmic antibodies (ANCA). Conventional treatments include…
Abstract Number: 2742 • 2017 ACR/ARHP Annual Meeting
A Retrospective Study Comparing the Phenotype and Outcomes of Patients with Polyarteritis Nodosa between UK and Turkish Cohorts
Omer Karadag^1,2, Abdulsamet Erden², Yelda Bilginer², Seerapani Gopaluni¹, Alper Sari², Berkan Armagan², Ihsan Ertenli², Seza Ozen² and David Jayne³, ¹Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom, ²Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ³Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Polyarteritis Nodosa (PAN) is a rare subgroup of the primary vasculitides. There are only two published cohorts describing demographic and clinical features of the disease.…